Chemotherapy and Radiotherapy for Gastrointestinal Cancers Daisuke Takahari 1 , Kei Muro 1 1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan Keyword: 食道癌 , 胃癌 , 大腸癌 , 化学療法 , 化学放射線療法 pp.1805-1815
Published Date 2009/11/25
DOI https://doi.org/10.11477/mf.1403101794
  • Abstract
  • Look Inside
  • Reference

 For esophageal cancer, chemotherapy must be used in all stages to improve clinical outcomes. With that general principle, survival after chemoradiotherapy is comparable to survival after surgery alone for stage I cancer. Preoperative chemotherapy is considered the new standard of care for stages II and III ; and systemic chemotherapy and chemoradiotherapy are commonly used for metastatic and locally advanced disease, respectively. For gastric cancer, outcomes of three important Japanese phase III studies, ACTS-GC, JCOG9912, and SPIRITS, have been recently reported. The results immediately set a new standard for gastric cancer in Japan. There is also hope that like trastuzumab, novel molecular targeting agents will be used in the near future. For colorectal cancer, the introduction of irinotecan and oxaliplatin therapy followed by molecular targeting agents such as bevacizumab and cetuximab, has improved overall survival to over 2 years from 6~8 months using the best supportive care. However, patients with KRAS mutations appear not to benefit from anti-EGFR antibody therapy with cetuximab or panitumumab. We have just started to practice “personalized” chemotherapy.

Copyright © 2009, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院